eJHaem · 2022 · 10 citations · 15 references
MedicinePharmacologyPharmacotherapyChemotherapyClinical PharmacologyImmunotherapyCombination ImmunotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyImmunotherapy SafetyMultiple MyelomaLenalidomide TherapyMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma TreatmentObservational Study EvaluationRefractory Multiple MyelomaRelapsed Multiple MyelomaSafety Profile Characterization
Abstract Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real‐world data are limited. This real‐world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in adults with RRMM. Data are presented for a subset of patients ( n = 383) who received carfilzomib in combination with lenalidomide and dexamethasone (KRd). The overall response rate (ORR) was 83.6% among 360 evaluable patients. Treatment responses were better when KRd was administered at earlier therapy lines than at later lines of therapy (ORR: second line, 85.3%; third line or later, 81.0%). In patients with the anti‐CD38 antibody‐refractory disease, ORR was higher when KRd was administered earlier than at later therapy lines (second line/third line, 75.0%; fourth line or later, 60.0%). An ORR of 68.1% and 82.0% was achieved in the lenalidomide‐refractory and not lenalidomide‐refractory subgroups, respectively. KRd was consistently administered per the European label (twice weekly dose of 27 mg/m 2 ) and the median time to discontinuation was 14.6 months. The safety profile of KRd was consistent with previous studies. These real‐world data highlight the effectiveness of KRd as a treatment for patients with RRMM, including those with disease refractory to lenalidomide or anti‐CD38 antibodies.
15
International Staging System for Multiple Myeloma
Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie et al. · Journal of Clinical Oncology · 2005 · 2.9K citations
Medicine, Hematology, Oncology +14
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +16